To read the full story, subscribe or sign in.

Inipharm to use its $35M series A for liver-related therapies

Nov. 11, 2020

Though founded in 2018, Inipharm Inc. has just closed on a $35 million series A financing designed to push its lead program through an IND filing and into the clinic to treat liver-related diseases.

BioWorld Financings Gastrointestinal Series A

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Illustration of female reproductive system with polycystic ovary

First atlas of the endometrium with polycystic ovary syndrome

BioWorld Science

Although the causes of polycystic ovary syndrome (PCOS) are unclear, researchers know this condition leads to endometrial dysfunction in women who have hormonal...

Another rebound as Sangamo inks $1.4B capsid deal with Lilly

BioWorld

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an...